Development of citral-based hydrogel for the treatment of oral candidosis: in vitro and in vivo study
摘要
Oral candidosis is very common and fungi resistance to drugs available on the market has been reported, as well as a high rate of recurrences. New treatment alternatives are studied.
ObjectiveThis study developed a citral-based hydrogel (CBH), performed the physical-chemical characterization and evaluated, in vitro, the microbial susceptibility to Candida spp. and the growth kinetics. It also analyzed acute in vivo toxicity and mutagenicity through the micronucleus test in mouse erythrocytes.
Materials and methodsThe following strains were used in the antifungal activity assays: C. albicans ATCC 10,231, C. glabrata ATCC 90,030, C. krusei ATCC 6258, C. tropicalis ATCC 750, C. parapsilosis ATCC 22,019 and clinical strains of C. albicans A4, C. albicans A5 and C. albicans A6. Microbial susceptibility was verified by the agar disk diffusion test and the effect on the growth kinetics of C. albicans (ATCC 10231). Acute toxicity and clastogenic and aneugenic potential were evaluated in Mus Musculus mice, line Swiss, age six weeks (CBH 2000 mg/kg). Data were analyzed by descriptive and inferential ANOVA and Tukey statistics.
ResultsCBH showed inhibition halos greater than or equal to 10 mm in diameter depending on the concentration analyzed, for all Candida strains tested. The product significantly inhibited the growth of C. albicans ATCC 10,231 at all different inoculum concentrations evaluated, between 15 and 120 min, when compared to the growth control. CBH did not induce signs of acute toxicity in mice submitted to gavage treatment at a single dose of 2000 mg/kg. CBH produced a statistically significant smaller number of micronuclei compared to the positive control (cyclophosphomide 50 mg/kg) in erythrocytes from mice.
ConclusionThe citral-based hydrogel proved to be a potential antifungal agent against Candida species, with low toxicity and mutagenicity.